You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSI-H/dMMR

Showing 1 - 25 of 2,558
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

Not yet recruiting
  • MSI-H/dMMR Gastroesophageal-junction Cancer
  • MSI-H/dMMR Gastric Cancer
  • (no location specified)
Oct 30, 2023

dMMR Colorectal Cancer Trial in Beijing (Cadonilimab)

Recruiting
  • dMMR Colorectal Cancer
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Apr 13, 2023

Neoadjuvant Envafolimab in Resectable and Locally Advanced

Not yet recruiting
  • Locally Advanced Rectal Carcinoma
  • MSI-High
  • (no location specified)
Dec 9, 2022

MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • +3 more
  • (no location specified)
Apr 23, 2023

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

Terminated
  • MSI-H/dMMR Solid Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 17, 2022

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Anti-PD-1 Antibody, Radiotherapy, Rectal Cancer Trial in Chengdu (Sintilimab, Hypofractionated Radiotherapy)

Recruiting
  • Anti-PD-1 Antibody
  • +4 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Apr 25, 2022

Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

Not yet recruiting
  • Gastric
  • Colorectal Adenocarcinoma
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital & Institute
Nov 1, 2023

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

    Not yet recruiting
    • Adenocarcinoma - GEJ
    • Gastric Adenocarcinoma
    • (no location specified)
    Sep 26, 2023

    Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)

    Recruiting
    • Gastric or Gastroesophageal Junction Adenocarcinoma
    • PD-1 inhibitor
    • Guangzhou, China
      Sun Yat-sen University Cancer Center
    Aug 9, 2023

    Registry Study in MSI/dMMR Solid Tumors

    Not yet recruiting
    • DMMR Cancer
    • +2 more
      • (no location specified)
      Aug 21, 2023

      Colonic Tumors Trial (Dostarlimab, CAPEOX, FOLFOX)

      Not yet recruiting
      • Colonic Neoplasms
      • Dostarlimab
      • +2 more
      • (no location specified)
      May 3, 2023

      DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

      Not yet recruiting
      • Endometrial Cancer
      • (no location specified)
      Feb 14, 2023

      Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

      Not yet recruiting
      • Metastatic Colorectal Cancer
      • HX008
      • Investigator's Choice Chemotherapy
      • Hefei, Anhui, China
      • +9 more
      Dec 8, 2022

      Tumors, Rectal Trial (Dostarlimab)

      Not yet recruiting
      • Neoplasms, Rectal
      • Dostarlimab
      • (no location specified)
      Feb 2, 2023

      Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

      Recruiting
      • Colorectal Carcinoma
      • Guangzhou, China
        Sun Yat-sen University
      Dec 29, 2022

      Rectal Tumors Trial in Cleveland (Pembrolizumab, External beam radiation, Capecitabine)

      Recruiting
      • Rectal Neoplasms
      • Cleveland, Ohio
        Cleveland Clinic, Case Comprehensive Cancer Center
      Jan 25, 2023

      Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

      Recruiting
      • Colorectal Cancer
      • +3 more
      • Neoadjuvant therapy with PD-L1 inhibitor
      • Guangzhou, Guangdong, China
        the Third Affiliated Hospital of Sun Yat-Sen University
      May 10, 2022

      Solid Tumor Trial in Beijing (KN035)

      Recruiting
      • Solid Tumor
      • KN035
      • Beijing, Beijing, China
        Peking University Cancer Hospital, Peking University
      Apr 5, 2022

      Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Houston

      Terminated
      Has Results
      • Locally Advanced Malignant Solid Neoplasm
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 22, 2022

      Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

      Active, not recruiting
      Has Results
      • Colorectal Carcinoma
      • (no location specified)
      Oct 28, 2022